Zacks Research Analysts Decrease Earnings Estimates for Zoetis Inc. (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Investment analysts at Zacks Research reduced their Q4 2024 earnings per share (EPS) estimates for shares of Zoetis in a report released on Monday, April 29th. Zacks Research analyst E. Bagri now forecasts that the company will earn $1.48 per share for the quarter, down from their previous forecast of $1.50. The consensus estimate for Zoetis’ current full-year earnings is $5.79 per share. Zacks Research also issued estimates for Zoetis’ Q1 2025 earnings at $1.49 EPS, Q2 2025 earnings at $1.65 EPS, FY2025 earnings at $6.38 EPS, Q1 2026 earnings at $1.66 EPS and FY2026 earnings at $6.94 EPS.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.15 EPS.

A number of other equities analysts also recently issued reports on ZTS. The Goldman Sachs Group increased their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays reduced their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $216.13.

Zoetis Trading Down 0.3 %

Shares of Zoetis stock opened at $159.17 on Tuesday. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The firm has a market cap of $72.80 billion, a price-to-earnings ratio of 31.39, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. Zoetis has a 52-week low of $144.80 and a 52-week high of $201.92. The company’s 50-day simple moving average is $170.66 and its 200-day simple moving average is $179.12.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is currently 34.12%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the sale, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 2,209 shares of company stock worth $371,293. Insiders own 0.16% of the company’s stock.

Institutional Trading of Zoetis

A number of large investors have recently made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC boosted its stake in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its stake in shares of Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the period. Private Wealth Management Group LLC acquired a new stake in Zoetis during the fourth quarter worth approximately $33,000. Webster Bank N. A. boosted its position in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the last quarter. Finally, Ramirez Asset Management Inc. purchased a new stake in Zoetis in the 3rd quarter worth approximately $35,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.